AstraZeneca is looking to increase its presence north of the US border. The UK pharma said it is budgeting $570 million to ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential ...

Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.

Teva, Astellas and AstraZeneca say they will participate in the next round of Medicare negotiations under the Inflation ...

UnitedHealth Group has named a new CEO to lead its health insurance business, following the murder of the division’s former ...

Purdue Pharma and the Sackler family have agreed to a $7.4 billion settlement in a longstanding legal battle over the ...

We’re in the first week of the second Trump administration, and it’s becoming clearer how it might impact healthcare ...

What will President Donald Trump's team do on healthcare? Nobody knows for sure. That was the general agreement among the policy experts who advise the drug industry last week at the JP Morgan ...

Catalent to make Galapagos' CAR-T therapy, Kindeva gets $129M DuoDote contract, Solarbiotech/GPC Bio/Eleszto merge, Afrigen ...